Название продукции:ethyl 2-[2-(morpholin-4-yl)cyclopent-2-en-1-ylidene]acetate
IUPAC Name:ethyl 2-[2-(morpholin-4-yl)cyclopent-2-en-1-ylidene]acetate
- CAS:380350-42-5
- Молекулярная формула:C13H19NO3
- Чистота:95%+
- Номер в каталоге:CM1046487
- Молекулярная масса:237.3
Упаковочная единица |
Доступно для заказа |
Цена ($) |
Количество |
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:380350-42-5
- Молекулярная формула:C13H19NO3
- Точка плавления:-
- Smiles-код:CCOC(=O)C=C1CCC=C1N1CCOCC1
- Плотность:
- Номер в каталоге:CM1046487
- Молекулярная масса:237.3
- Точка кипения:
- Номер Mdl:
- Хранение:
Category Infos
- Morpholines
- Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.
- morpholine price
- if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.
Column Infos
- Etrasimod
- Etrasimod is a new generation of oral S1P receptor modulator, which can specifically bind to S1P receptors 1, 4, and 5. It is being studied for a range of immune inflammatory diseases, including ulcerative colitis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. At present, the highest stage of research and development of the drug is to apply for marketing, which is used to treat ulcerative colitis and is expected to be approved by FDA in this month.